Vertex Pharmaceuticals, Inc. (VRTX) Misses Q1 EPS by 11c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $466.79 +3.36%
Revenue Growth %: +8.4%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +8.4%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q1 EPS of $0.55, $0.11 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $438.7 million versus the consensus estimate of $473.37 million.
Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
- Sun Communities names Ileana McAlary as general counsel and EVP
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
